We’re bringing together scientists, clinicians, and innovators from around the world for a one-day deep dive into one of the most fascinating emerging topics in neuroscience and medicine: the Brain-Nose Interface (BNI).
We are exploring the direct link between the nose and the brain – with exciting implications for diagnostics, therapeutics and interdisciplinary science.

Join us in Munich for an inspiring day of panel talks, discussion, and community building.

Date:

November 21, 2025

Location:

Hotel Maria’s Platzl, Munich, Germany

What to Expect:

  • Interdisciplinary Program – Explore groundbreaking work at the intersection of:
    • Anatomy & Physiology of the Brain-Nose Interface
    • Brain Biomarkers in Research and Clinical Use
    • Opportunities of the Brain-Nose Interface
  • Expert Speakers – A carefully selected group of international thought leaders (speaker highlights coming soon!)
  • Community First – Meet fellow researchers, clinicians, and industry partners passionate about advancing the BNI

Why BNI, Why Now?

The brain-nose interface plays a pivotal role in neurology, diagnostics, and therapeutic innovation and could have tremendous potential to improve the healthcare industry. Yet it remains underexplored. Our mission is to:

  • Spark a lasting interdisciplinary dialogue
  • Lay the groundwork for future research collaborations
  • Raise awareness and visibility for this emerging field

 

Let’s shape the future of the BNI field, together.

Coming Soon! Stay Tuned for:

  • Confirmed speaker highlights
  • Program schedule
  • Accommodation & travel details
  • Sponsor and partner announcements

Questions?

Feel free to contact us at events@noselab.com.

This event is certified for CME credit

Join us! Register Now and Become a Part of the BNI Community:

Noselab GmbH is a leading innovator in diagnostic breakthrough technology, specializing in the early detection and management of neurodegenerative diseases. Leveraging its revolutionary diagnostic platform, which analyzes nasal Cerebro-Spinal Fluid (CSF) biomarkers, Noselab aims to transform disease diagnosis, staging, and therapy monitoring to improve patient outcomes. As a member of the Munich Bio-M cluster, Noselab collaborates with leading experts and institutions to drive innovation and foster collaboration in biomedical research and development.

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. These risks and uncertainties include, but are not limited to, the risks and uncertainties associated with the development of diagnostic technologies, the success of clinical trials, the regulatory approval process, market acceptance of products, competition, intellectual property rights, and other risks inherent in the diagnostic development industry.

Additionally, any statements regarding future performance, achievements, or financial outlook of the Company are forward-looking statements and are subject to risks and uncertainties. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.

Investors and potential investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement.